These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 30914057)
1. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Ladanyi M; Sanchez Vega F; Zauderer M Genome Med; 2019 Mar; 11(1):18. PubMed ID: 30914057 [TBL] [Abstract][Full Text] [Related]
2. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Shrestha R; Nabavi N; Lin YY; Mo F; Anderson S; Volik S; Adomat HH; Lin D; Xue H; Dong X; Shukin R; Bell RH; McConeghy B; Haegert A; Brahmbhatt S; Li E; Oo HZ; Hurtado-Coll A; Fazli L; Zhou J; McConnell Y; McCart A; Lowy A; Morin GB; Chen T; Daugaard M; Sahinalp SC; Hach F; Le Bihan S; Gleave ME; Wang Y; Churg A; Collins CC Genome Med; 2019 Feb; 11(1):8. PubMed ID: 30777124 [TBL] [Abstract][Full Text] [Related]
3. Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy. Ghafoor A; Hassan R J Thorac Oncol; 2022 Jul; 17(7):862-864. PubMed ID: 35750452 [No Abstract] [Full Text] [Related]
4. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma. Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708 [TBL] [Abstract][Full Text] [Related]
5. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777 [TBL] [Abstract][Full Text] [Related]
6. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383 [TBL] [Abstract][Full Text] [Related]
7. Targeting BAP1: a new paradigm for mesothelioma. Schunselaar LM; Zwart W; Baas P Lung Cancer; 2017 Jul; 109():145-146. PubMed ID: 28342657 [TBL] [Abstract][Full Text] [Related]
8. Loss of expression of BAP1 predicts longer survival in mesothelioma. Farzin M; Toon CW; Clarkson A; Sioson L; Watson N; Andrici J; Gill AJ Pathology; 2015 Jun; 47(4):302-7. PubMed ID: 25938359 [TBL] [Abstract][Full Text] [Related]
9. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application]. Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072 [No Abstract] [Full Text] [Related]
10. Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma. Badhai J; Landman N; Pandey GK; Song JY; Hulsman D; Krijgsman O; Chandrasekaran G; Berns A; van Lohuizen M Cancer Res Commun; 2024 Jan; 4(1):18-27. PubMed ID: 38054839 [TBL] [Abstract][Full Text] [Related]